India to Start Clinical Trials of US-Based Second Generation, Low-Cost Covid-19 Vaccine
India will soon start clinical trials of US-based Akston Biosciences second-generation Covid-19 vaccine — one of the most promising candidates that can be rapidly produced at a low cost, suitable for repeated dosing if immunity wanes and requires no refrigeration. The vaccine samples have been sent to the Central Drugs Laboratory in Kasauli as a protocol for checking the safety prior to starting its use in clinical trials. Read more >>